Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04560972
Title LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors City of Hope Medical Center

lung small cell carcinoma


Atezolizumab + Carboplatin + Etoposide + LB-100

Atezolizumab + LB-100

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.